Form of Warrant Amendment Agreement
Exhibit 4.4
August 20, 2024
Holder of Warrants to Purchase Common Stock set forth on Exhibit A attached hereto
Re: Amendment to Existing Warrants
Dear Holder:
Reference is hereby made to the underwritten offering on or about the date hereof (the “Offering”) by Reviva Pharmaceuticals Holdings, Inc. (the “Company”) of its common stock, par value $0.0001 per share (“Common Stock”), and/or other securities of the Company (collectively, the “Securities”).
This letter confirms that, in consideration for the Holder’s participation in the Offering and purchase of Securities in the Offering (the “Purchase Commitment”) and the payment of an additional $0.125 per share of Common Stock issuable upon exercise of the Existing Warrants (as defined below) pursuant the terms of the Underwriting Agreement entered into in connection with the Offering (the “Cash Consideration”), the Company hereby amends, effective as of the closing of the Offering, the Common Stock purchase warrants set forth on Exhibit A hereto (the “Existing Warrants”) by (i) reducing the Exercise Price (as defined therein) of the Existing Warrants to $0.7964 per share and (ii) amending the expiration date of the Existing Warrants to five years following the closing of the Offering (the “Warrant Amendment”). The Warrant Amendment shall be effective upon the closing the Offering and the satisfaction of the other terms and conditions referenced below.
The Warrant Amendment is subject to the consummation of the Offering, the payment of the Cash Consideration by the Holder and the Holder’s satisfaction of the Purchase Commitment. In the event that either (i) the Offering is not consummated, or (ii) the Holder does not satisfy the Purchase Commitment or pay the Cash Consideration, the Warrant Amendment shall be null and void and the provisions of the Existing Warrants in effect prior to the date hereof shall remain in effect.
Except as expressly set forth herein, the terms and provisions of the Existing Warrants shall remain in full force and effect after the execution of this letter and shall not be in any way changed, modified or superseded except by the terms set forth herein.
From and after the effectiveness of the Warrant Amendment, the Company agrees to promptly deliver to the Holder, upon request, amended Existing Warrants that reflect the Warrant Amendments in exchange for the surrender for cancellation of the Holder’s Existing Warrants to be amended as provided herein.
[Signature Page Follows]
IN WITNESS WHEREOF, the parties hereto have caused this agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
REVIVA PHARMACEUTICALS HOLDINGS, INC.
| By: |
Name: Laxminarayan Bhat
Title: Chief Executive Officer
Name of Holder: ___________________________________________________________________________________________________
Signature of Authorized Signatory of Holder: ____________________________________________________________________________
Name of Authorized Signatory: ________________________________________________________________________________________________
[Signature Page to Warrant Amendment Agreement]
EXHIBIT A
EXISTING WARRANTS
|
|
|
